 I. To compare disease-free survival DFS of standard risk pediatric Philapdelphia chromosome Ph acute lymphoblastic leukemia ALL treated with continuous imatinib mesylate imatinib combined with either a high-risk Childrens Oncology Group COGBerlin-Frankfurt-Munster BFM ALL chemotherapy backbone or the more intensive European EsPhALL chemotherapy backbone. 